---
title: "Obefazimod (ABX464) in Ulcerative colitis: Dosage forms and strengths"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Dosage forms and strengths. Topics: Investigational dosage form: 25 mg and 50 mg oral capsules, Pharmaceutical forms in the EU paediatric investigation plan: hard capsule and an age-appropriate oral liquid, and Pediatric 50 mg minitablet formulation compared with the adult capsule in healthy participants (ABX464-911). 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Investigational dosage form: 25 mg and 50 mg oral capsules

| Field | Quoted record |
| --- | --- |
| International nonproprietary name | “Obefazimod” |
| Strengths | “25 mg capsule”; “50 mg capsule” |
| Route of administration | “Oral” |
| Packaging | “Each blister card (=kit) contains 35 capsules.” |
| Blister cards | “IMP will be packaged in child-resistant blister cards with blinded labels.” |

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

> “Obefazimod is formulated as an oral solid capsule.”
> “We have successfully scaled-up active pharmaceutical ingredients and drug product processes, and we have a large supply of active pharmaceutical ingredients and capsules available for clinical trials.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.2-2"></a>

### Pharmaceutical forms in the EU paediatric investigation plan: hard capsule and an age-appropriate oral liquid

| Field | Quoted record |
| --- | --- |
| Pharmaceutical forms | “Capsule, hard”; “Age-appropriate oral liquid dosage form” |
| Route of administration | “Oral use” |
| Quality-related study | “Development of an age-appropriate oral liquid dosage form.” |

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.2.2-3"></a>

### Pediatric 50 mg minitablet formulation compared with the adult capsule in healthy participants (ABX464-911)

> “Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation”
> “Participants will receive a single oral dose of obefazimod Capsule administered with water”
> “Participants will receive a single oral dose of obefazimod Minitablet with either Apple sauce, Chocolate pudding, Yogurt, Water”
> “Pediatric formulation”

Source: [ClinicalTrials.gov NCT07453784](https://clinicaltrials.gov/study/NCT07453784)

<a id="topic-2.1.2.2-4"></a>

### Commercial dosage form and strengths

No evidence found.

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
